AbCellera Biologics
ABCL
147 hedge funds and large institutions have $338M invested in AbCellera Biologics in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 38 increasing their positions, 47 reducing their positions, and 25 closing their positions.
6% less call options, than puts
Call options by funds: $1.08M | Put options by funds: $1.16M
2.45% less ownership
Funds ownership: 41.3% → 38.85% (-2.4%)
5% less funds holding
Funds holding: 154 → 147 (-7)
19% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 47
20% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 25
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less capital invested
Capital invested by funds: $547M → $338M (-$209M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$17.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.68M |
| 3 |
Two Sigma Investments
New York
|
+$2.2M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$2.13M |
| 5 |
EAM
Exome Asset Management
New York
|
+$1.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$11.5M |
| 2 |
CC
Casdin Capital
New York
|
-$10.7M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$4.8M |
| 4 |
Lazard Asset Management
New York
|
-$3.51M |
| 5 |
Man Group
London,
United Kingdom
|
-$3.5M |
ABCL Hedge Fund Activity: Q2 2024 in Review
147 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q2 2024, worth a combined $338M — down 38% from $547M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ABCL and 20 opened new positions — a net loss of 5 holders — while 47 trimmed existing stakes and 38 added.
The largest buyer was UBS AM, opening a new position worth an estimated $17.4M. The largest seller was Capital World Investors, cutting an estimated $11.5M.
- 147 institutional investors held AbCellera Biologics (ABCL) as of Q2 2024, down from 154 in Q1 2024.
- Funds reported $338M of AbCellera Biologics stock for Q2 2024, down 38% quarter-over-quarter.
- 20 funds opened new AbCellera Biologics positions in Q2 2024 and 25 closed out, a net change of -5 holders.
- The largest AbCellera Biologics buyer in Q2 2024 was UBS AM, an estimated $17.4M added.
- The largest AbCellera Biologics seller in Q2 2024 was Capital World Investors, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2024.